The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Cytokine Release Syndrome Treatment Market Expected To Change From 2026 To 2030?
The market for cytokine release syndrome treatment has seen substantial expansion recently. Projections indicate a rise from $1.42 billion in 2025 to $1.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.6%. This historical growth is attributable to factors such as the rise in advanced immunotherapy treatments, broader adoption of CAR-T cell therapy, the availability of corticosteroids for immune modulation, heightened clinical understanding of cytokine storms, and enhancements in critical care infrastructure.
The cytokine release syndrome treatment market is projected for significant expansion in the coming years. It is anticipated to reach $2.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.3%. This growth during the forecast period is primarily driven by factors such as the increasing application of next-generation immunotherapies, rising investments in cytokine modulation research, the expansion of oncology treatment centers, a growing focus on personalized immune management, and the development of novel anti-inflammatory biologics. Prominent trends anticipated in this period encompass the increasing use of IL-6 and IL-1 targeted therapies, the rising adoption of monoclonal antibodies for CRS management, the broadening of hospital-based CRS treatment protocols, a heightened integration of early diagnostic monitoring, and improved supportive care management strategies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20542&type=smp
Which Strong Drivers Are Impacting The Cytokine Release Syndrome Treatment Market Growth?
The rising frequency of cancer therapies is anticipated to stimulate the expansion of the cytokine release syndrome (CRS) treatment market moving forward. This escalation in cancer treatments is fueled by the growing global incidence of cancer and advancements in diagnostic technologies, which facilitate earlier detection and a broader spectrum of treatment options. Additionally, improved survival rates and widened access to healthcare services contribute to the increasing demand for these therapies. CRS treatment typically includes supportive care, anti-cytokine interventions, and continuous monitoring to manage symptoms and alleviate the inflammatory reaction triggered by cancer treatments. For instance, in May 2024, as per the National Health Service (NHS), a UK-based healthcare system, nearly 340,000 individuals received their initial treatment for cancer over the past year, from April 2023 to March 2024. Furthermore, urgent suspected cancer referrals reached a new record in March 2024, with 12,554 patients seen per working day, marking a new high that exceeded the previous record of 12,376 patients seen per working day in July 2023. Thus, the increasing prevalence of cancer treatments is a significant driver for the cytokine release syndrome treatment market.
What Segment Categories Shape The Cytokine Release Syndrome Treatment Market Segment Landscape?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
Which Trends Are Contributing To Changes In The Cytokine Release Syndrome Treatment Market?
Leading companies in the cytokine release syndrome treatment market are developing advanced drug delivery methods, including intravenous infusion, to improve treatment accuracy, decrease side effects, and enhance patient results. Intravenous infusion facilitates the quick and precise delivery of drugs into the bloodstream, ensuring rapid therapeutic action. For example, in September 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, obtained regulatory approval for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody, from the Ministry of Health, Labor, and Welfare, a Japan-based government authority, to manage cytokine release syndrome (CRS) arising from various cancer therapies. Actemra Intravenous Infusion (available in 80 mg, 200 mg, and 400 mg doses) serves as an additional indication in treating cytokine release syndrome (CRS) caused by cancer therapy. With this updated indication, Actemra can now function as an anti-cytokine therapy for CRS resulting from cancer treatments beyond just tumor-specific T-cell infusion therapy.
Who Are The Companies Operating Across The Cytokine Release Syndrome Treatment Market Value Chain?
Major companies operating in the cytokine release syndrome treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd., Incyte Corporation, Swedish Orphan Biovitrum AB (publ), Bio-Techne Corporation, GenScript Biotech Corporation, Abcam plc, Applied Biological Materials Inc., Poolbeg Pharma, arigo Biolaboratories Corp., CytoAgents Inc, bluebird bio Inc.
Get The Full Cytokine Release Syndrome Treatment Market Report:
Which Region Accounts For The Largest Portion Of The Cytokine Release Syndrome Treatment Market?
North America was the largest region in the cytokine release syndrome treatment market in 2025. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cytokine Release Syndrome Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Treatment Market 2026, By The Business Research Company
Drugs For Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model